Erratum: Antihypertensive Drug Use and New-Onset Diabetes in Female Patients with Coronary Artery Disease: A Population-based Longitudinal Cohort Study (Medicine 94:36 (e1495) DOI: 10.1097/MD.0000000000001495);Antihypertensive drug use and new-onset diabetes in female patients with coronary artery disease: A population-based longitudinal cohort study

Medicine (United States)

Volumn 94, Issue 36, 2015, Pages

  Liou, Yi Sheng ^a   Chen, Hung Yi ^b   Tien, Lyun ^c   Gu, Yi Sian ^b   Jong, Gwo Ping ^d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; VASODILATOR AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIURETIC THERAPY; DRUG USE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NEW ONSET DIABETES; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; TAIWAN; AGED; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 84941624813     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/01.md.0000481303.19880.00     Document Type: Erratum

References (32)

1. Park GM, An H, Lee SW, et al. Risk score model for the assessment of coronary artery disease in asymptomatic patients with Type 2 diabetes. Medicine. 2015;94:e508.
2. Kalyani RR, Lazo M, Ouyang P, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2014;37:830-838.
3. Efird JT, O'Neal WT, Griffin WF, et al. Increased coronary artery disease severity in black women undergoing coronary bypass surgery. Medicine. 2015;94:e552.
4. de la Hera JM, García-Ruiz JM, Martínez-Camblor P, et al. Real incidence of diabetes mellitus in a coronary disease population. Am J Cardiol. 2012;111:333-338.
5. Rajala U, Qiao Q, Laakso M, et al. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pra. 2000;50:231-239.
6. Liou YS, Ma T, Tien L, et al. The relationship between antihypertensive combination therapies comprising diuretics and/or betablockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study. Hypert Res. 2009;32:231-239.
7. ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
8. Pepine CJ, Handberg M, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805-2816.
9. Dahlof BE, Devereux RB, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
10. Vardeny O, Uno H, Braunwald E, et al. Opposing effects of b blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011;107:1705-1709.
11. Ogihara T, Fujimoto A, Nakao K, et al. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther. 2008;6:1195-1201.
12. Weycker D, Edelsberg J, Vincze G, et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Human Hypert. 2007;21:374-380.
13. Chang CH, Chang YC, Wu LC, et al. Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2014;13:91.
14. Liou YS, Ma T, Tien L, et al. The relationship between antihypertensive combination therapies comprising diuretics and/or betablockers and the risk of new-onset diabetes-A retrospective longitudinal cohort study. Hypert Res. 2009;32:496-499.
15. Jong GP, Chang MH, Tien L, et al. Antihypertensive drugs and new-onset diabetes: a retrospective longitudinal cohort study. Cardiovasc Ther. 2009;27:159-163.
16. Zidek W, Schrader J, Lüders S, et al. Ramipril-based versus diureticbased antihypertensive primary treatment in patients with prediabetes (ADaPT) study. Cardiovasc Diabetol. 2012;11:1-11.
17. Elliott WJ. Differential effects of antihypertensive drugs on newonset diabetes. Curr Hypertens Rep. 2005;7:249-256.
18. Chatterjee R, Yeh HC, Edelman D, et al. Potassium and risk of Type 2 diabetes. Expert Rev Endocrinol Metab. 2011;6:665-672.
19. Blackburn DF, Wilson TW. Antihypertensive medications and blood sugar: theories and implications. Can J Cariol. 2006;22:229-233.
20. Shen L, Shah BR, Reyes EM, et al. Role of diuretics, b blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347:f6745.
21. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Int Med. 2006;166: 2191-2201.
22. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006;29:1065-1070.
23. Padwal R, Mamdani M, Alter DA, et al. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care. 2004;27:2458-2463.
24. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
25. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
26. Padwal R, Laupacis A. Antihypertensive Therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27:247-255.
27. Fukao K, Shimada K, Hiki M, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azeldipine and amlodipine on glucose tolerance and endothelial function-a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:1-7.
28. Stohr R, Marx N. Renin-angiotensin-aldosterone system antagonists and the prevention of type 2 diabetes mellitus. Curr Pharm Design. 2012;18:958-962.
29. Holcomb SS. Selection of antihypertensive agents in patients at risk for diabetes. Curr Hypertens Rep. 2005;7:461-465.
30. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. New Engl JMed. 2006;355:1551-1562.
31. Barzilay JI, Gao P, Rydén L, et al. Effects of telmisartan on glucose levels in people at high risk for cardiovascular dsease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011;34:1902-1907.
32. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2012;15:004643.